ITPRIPL1 and breast carcinoma: ITPRIPL1 promoter methylation was also observed in 83.3% of Stage 0 breast cancer patients, 77.1% of patients with smaller-sized tumors and 74.3% of patients without lymph node metastasis (Table 3).